Markets

Biotech ETF (XBI) Hits a New 52-Week High

For investors seeking momentum, SPDR S&P Biotech ETF XBI is probably on the radar now. The fund just hit a 52-week high and is up about 45.5% from its 52-week low price of $64.38/share.

But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:

XBI in Focus

XBI focuses on the biotechnology segment of the U.S. market and offers equal-weight exposure across stocks. It is spread across various market spectrums, with 65% allocated to small caps, 20 to mid caps and the rest to large caps. The fund charges investors 35 basis points a year in fees (see: all the Healthcare ETFs here).

Why the Move?

The biotech corner of the broad healthcare sector has been an area to watch lately, given the astounding performance at the start of the fourth quarter. A slew of positive news, including study results, regulatory backdrop and deal activities, and better-than-expected corporate earnings have fueled the rally in the sector. Additionally, uncertainty over the trade deal added to the positives given that the sector is non-cyclical in nature, which provides a defensive tilt to the portfolio.

More Gains Ahead?

Currently, XBI has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting continued outperformance in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>


Click to get this free report

SPDR S&P Biotech ETF (XBI): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

ETFs

Latest Markets Videos